Date: 2013-09-26
Type of information: Licensing agreement
Compound: antibody platform
Company: Adimab (USA) NovoNordisk (Denmark)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism:
Disease:
Details: * On September 26, 2013, Adimab, a US company dedicated to the discovery and optimization of fully human monoclonal and bispecific antibodies, has announced its 3rd technology transfer, by licensing the Adimab technology to Novo Nordisk. Adimab will receive upfront payments, annual licensing fees and royalties on commercialized products resulting from Novo Nordisk’s use of the Adimab technology. Under the terms of the agreement, Novo Nordisk will have a non-exclusive field license to the Adimab antibody discovery platform and a unique custom antibody library that is exclusive to Novo Nordisk. Novo Nordisk is allowed to use the Adimab platform on an unlimited number of targets for IgG discovery, optimization, humanization and bispecifics. In addition, Novo Nordisk may access improvements to the platform during the term of the collaboration. Adimab will receive a series of payments including upfront payments, research and development milestones, plus royalties and commercial milestones on all therapeutic products generated from the Adimab platform.
Over the past four years, Adimab has established numerous partnerships with leading pharmaceutical companies, including Merck, Roche, Novartis, Eli Lilly, Genentech, Biogen Idec, Novo Nordisk, Human Genome Sciences, Gilead, Kyowa Hakko Kirin, GSK, and Celgene. Adimab’s partnerships range from single-target funded discovery projects, to larger multi-target funded discovery collaborations. In 2013, Adimab started transferring its antibody discovery platform and custom antibody libraries to pharmaceutical companies for internal use. These collaborations focus on IgG discovery, optimization, humanization and/or bispecifics for therapeutic products.
By the first quarter of 2014, Adimab expects to have deployed its technology to three partner sites (GSK, Biogen Idec and Novo Nordisk). Adimab forecasts additional transfers throughout 2014, driven by the broad interest in its technology transfer program.
Financial terms:
Latest news:
